US Markets
GSK

EU wraps up Sanofi talks aimed at securing coronavirus vaccine

Credit: REUTERS/BENOIT TESSIER

The European Union's executive on Friday wrapped up talks with French drugmaker Sanofi aimed at securing its COVID-19 vaccine for the 27-country EU bloc.

BRUSSELS, July 31 (Reuters) - The European Union's executive on Friday wrapped up talks with French drugmaker Sanofi SASY.PA aimed at securing its COVID-19 vaccine for the 27-country EU bloc.

"The envisaged contract with Sanofi would provide for an option for all EU Member States to purchase the vaccine," the European Commission said in a statement.

"It is envisaged that, once a vaccine has proven to be safe and effective against COVID-19, the Commission would have a contractual framework in place for the purchase of 300 million doses, on behalf of all EU member states."

Sanofi is working on two vaccine projects including one in partnership with GlaxoSmithKline GSK.L.

(Reporting by Foo Yun Chee; Editing by Andrew Cawthorne)

((foo.yunchee@thomsonreuters.com; +32 2 287 6844; Reuters Messaging: foo.yunchee.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GSK

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More